The Commonwealth Bank of Australia wants a judge to ensure it doesn’t get hit with double the cost for work defending two shareholder class actions brought by rival plaintiffs law firms.
Wealthy Chinese-Australian businessman Chau Chak Wing has won $280,000 in damages in his defamation case against the Sydney Morning Herald over an article he said falsely linked him to an international bribery scandal.
Law firm Piper Alderman said Friday it would defend a sex discrimination case brought by a leading female partner against the firm’s partnership, saying it did “not tolerate inappropriate workplace behaviour of any kind”.
DLA Piper appears to have settled a case brought by a Queen’s Counsel alleging it skipped out on $274,000 in fees because the firm’s client had not paid its bill.
Maurice Blackburn has persuaded a judge to lift a temporary injunction that blocked the law firm from going ahead with plans to unveil a replica of the iconic New York statue, Fearless Girl, at Melbourne’s Federation Square for International Women’s Day.
A female Piper Alderman partner has filed a sex discrimination lawsuit against the firm’s other partners and has won a temporary injunction blocking the partnership from ousting her.
The Construction, Forestry, Maritime, Mining and Energy Union has lost a battle with liquidators for failed labour hire business One Key Workforce over access to $1 million it said was owed in unpaid wages only to its members.
The Full Federal Court on Thursday will hear arguments in an employment case that calls into question the meaning of the personal leave provisions of the Fair Work Act and could have significant ramifications for how companies calculate the entitlement for shift workers.
Generic drug maker Sandoz must pay $26.34 million to Danish pharmacuetical giant Lundbeck and a subsidiary for infringing the Australian patent behind the blockbuster antidepressant Lexapro, a judge has found.
Drug maker Neurim Pharmaceuticals has won a bid to amend its Australian patent for top selling sleeping pill Circadin over the protests of two generic pharmaceutical companies, whch argued Neurim had purposely delayed the application to gain an unfair advantage in its infringement suit.